A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer (clinicaltrials.gov) - Aug 29, 2025 - P1/2 | N=9 | Terminated | Sponsor: Alaunos Therapeutics | Completed ➔ Terminated; The study was terminated after 9 subjects had enrolled under Protocol Amend 1 because of slower than expected accrual. Protocol Amendment 2 (16 May 2016) was submitted to the FDA and, based on the decision of the PI, was not submitted to the IRB.
Trial termination • Breast Cancer • Oncology • Solid Tumor
|